Trial Profile
Continue Providing Care for Patient Who Participated in the BIA 9-1067-302 Clinical Trial
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Sep 2020
Price :
$35
*
At a glance
- Drugs Opicapone (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms BIPARK-extension
- 03 Sep 2020 According to a Neurocrine Biosciences media release, data from this trial will be presented at the upcoming virtual scientific meetings, 2020 Psych Congress on September 10 to 13 and the MDS Virtual Congress 2020 on September 12 to 16
- 12 Mar 2020 Status changed from not yet recruiting to completed.
- 20 May 2013 New trial record